Table 2. Patient disposition.
| n (%) | Arm A: 840/420 mg pertuzumab, n=15 | Arm B: 840 mg q3w pertuzumab, n=15 |
|---|---|---|
| Completed six cycles of pertuzumab |
14 (93.3) |
11 (73.3) |
| Still on treatment |
7 (46.7) |
3 (20.0) |
| Discontinued treatment |
8 (53.3) |
12 (80.0) |
| Safety |
0 (0.0) |
2 (13.3) |
| Adverse event | 0 (0.0) | 1 (6.7) |
| Death |
0 (0.0) |
1 (6.7) |
| Non-safety |
8 (53.3) |
10 (66.7) |
| Physician decision | 0 (0.0) | 1 (6.7) |
| Progression of disease | 8 (53.3) | 8 (53.3) |
| Withdrawal by patient | 0 (0.0) | 1 (6.7) |